David Chang compensation by year
Allogene Therapeutics Summary Compensation Table · all 8 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Salary | $362,413 | $600,000 | $675,000 | $695,000 | $724,000 | $724,000 | $724,000 | $724,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $8,948,152 | $4,651,970 | $0 | $2,717,669 | $0 | $7,996,888 | $0 | $2,409,537 |
| Option awards | $3,070,331 | $5,327,140 | $6,550,535 | $6,352,635 | $13,697,357 | $5,070,365 | $2,401,683 | $2,588,329 |
| Non-equity incentive | $217,641 | $363,000 | $506,250 | $396,150 | $376,480 | $270,595 | $329,420 | $400,010 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $250,000 | $250,000 | $83,256 | $0 | $0 | $0 | $10,145 | $14,217 |
| Total | $12,848,537 | $11,192,110 | $7,815,041 | $10,161,454 | $14,797,837 | $14,061,848 | $3,465,248 | $6,136,093 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Allogene Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001628280-26-028948, and prior-year filings.
How this page was built: the Allogene Therapeutics, Inc. filed document, accession 0001628280-26-028948. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 1,480,357 | $2,028,089 | — |
| PSU | 689,855 | $945,101 | — |
| RSU | 552,174 | $756,478 | — |
| RSU | 222,054 | $304,214 | — |
| RSU | 211,866 | $290,256 | — |
| Option | 405,722 | — | $3.20 |
| Option | 1,952,130 | — | $1.94 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Allogene Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Allogene Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| David Chang · this page | President and Chief Executive Officer | $6,136,093 |
| Zachary Roberts | Chief Medical Officer and Executive Vice President of Research and Development | $1,987,723 |
| Geoffrey Parker | Executive Vice President and Chief Financial Officer | $1,943,962 |
Board service
Allogene Therapeutics board · FY2023–FY2025How this board is paid
Company policy: Allogene Therapeutics pays directors a $40,000 cash retainer and $300,000 in RSUs/Options. As stated in Allogene Therapeutics's FY2025 proxy.
The full Allogene Therapeutics compensation record
free company briefThis page is one person within Allogene Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Allogene Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Allogene Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Allogene Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.